The Sage Commons is a novel information platform being built by an international partnership of researchers and stakeholders to define the molecular basis of disease and guide the development of effective human therapeutics and diagnostics.
The Sage Commons will be used to integrate diverse molecular mega-data sets, to build predictive bionetworks and to offer advanced tools proven to provide unique new insights into human disease biology. Users will also be contributors that advance the knowledge base and tools through their cumulative participation.
The public access mission of the Sage Commons requires the development of a new strategic and legal framework to protect the rights of contributors while providing widespread access to integrative genomics resources.
Anne co-founded 23andMe in 2006 after a decade spent in healthcare investing, focused primarily on biotechnology companies. Her hope was to empower consumers with access to their own genetic information and to create a way to generate more personalized information so that commercial and academic researchers could better understand and develop new drugs and diagnostics. Presently, 23andMe has built one of the world's largest databases of individual genetic information. Its novel, web-based research approach allows for the rapid recruitment of participants to many genome-wide association studies at once, reducing the time and money needed to make new discoveries, and the company has created a proven and standardized resource for finding new genetic association and confirming genetic loci discovered by others. Under Anne's leadership 23andMe has made significant advances in bringing personalized medicine directly to the public. Anne graduated from Yale University with a BS in Biology. Getting access to and understanding her own genetic information had always been one of her ambitions.